Uncategorized

UCB bets $2 billion on Candid’s T cell engager ambitions

UCB bets $2 billion on Candid’s T cell engager ambitions

Published

4 hours ago

on

Ken Song has done it again.

The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies.

UCB is paying $2 …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version